PARP inhibitors target defective DNA repair in cancers with BRCA 1/2 mutations by blocking the repair of single-strand breaks, while leaving the double-strand breaks, thereby causing death of the BRCA 1/2-mutant cancer cells. This evidence concerns the gene PARP1 and cancer.